Maze Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Maze Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-51.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 72% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-23.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 58% of Healthcare companies in United States.
Cash Cushion Ratio
+18%Cash, after subtracting all debt, equals 18% of its market value (net cash).
Higher than 61% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Maze Therapeutics, Inc. made a loss over the last year. Maze Therapeutics, Inc. owes $0.15 for every $1 it owns. Maze Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMaze Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.80The share price is 3.80 times Maze Therapeutics, Inc.'s book value per share, higher than 64% of Healthcare companies in United States.
Market cap
$1.7 BThe total market value of all of Maze Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 72% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$453 MWhat Maze Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.16Net worth divided by the number of shares. The share price of $31.01 is 3.8 times this, which is the P/B above.
Return on equity (ROE)
-37.4%Maze Therapeutics, Inc. lost 37.4% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
Owes vs Owns
0.15×Maze Therapeutics, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NoneMaze Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossMaze Therapeutics, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Cash vs debt
Net cashMaze Therapeutics, Inc. held $319 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Maze Therapeutics, Inc.: $1.7 B ÷ $453 M (30 Jun 2026) = 3.8.
What is Maze Therapeutics, Inc.'s return on equity?
Maze Therapeutics, Inc. lost 37.4% of its shareholders' money over the last year, higher than 57% of Healthcare companies in United States.
How much does Maze Therapeutics, Inc. owe compared with what it owns?
Maze Therapeutics, Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does Maze Therapeutics, Inc. pay a dividend?
No. Maze Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.